HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.

Related Articles

HIF-prolyl hydroxylases as therapeutic targets in erythropoiesis and iron metabolism.

Hemodial Int. 2017 Jun;21 Suppl 1:S110-S124

Authors: Haase VH

Abstract
A classic response to systemic hypoxia is the increase in red blood cell production. This response is controlled by the prolyl hydroxylase domain/hypoxia-inducible factor (HIF) pathway, which regulates a broad spectrum of cellular functions. The discovery of this pathway as a key regulator of erythropoiesis has led to the development of small molecules that stimulate the production of endogenous erythropoietin and enhance iron metabolism. This review provides a concise overview of the cellular and molecular mechanisms that govern HIF-induced erythropoietic responses and provides an update on clinical experience with compounds that target HIF-prolyl hydroxylases for anemia therapy.

PMID: 28449418 [PubMed - indexed for MEDLINE]

http://ift.tt/2yyheK8